![]() |
Volumn 39, Issue 1, 2012, Pages 90-91
|
Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections
|
Author keywords
[No Author keywords available]
|
Indexed keywords
DAPTOMYCIN;
POLYPEPTIDE ANTIBIOTIC AGENT;
TEICOPLANIN;
VANCOMYCIN;
ADULT;
AGED;
CELLULITIS;
COMPLICATED SKIN AND SOFT TISSUE INFECTION;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG FATALITY;
DRUG WITHDRAWAL;
FRANCE;
GERMANY;
HUMAN;
LETTER;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
PHASE 3 CLINICAL TRIAL;
POLAND;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
SKIN INFECTION;
SOFT TISSUE INFECTION;
SPAIN;
STAPHYLOCOCCUS AUREUS;
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;
TREATMENT OUTCOME;
UNITED KINGDOM;
AGED;
ANTI-BACTERIAL AGENTS;
DAPTOMYCIN;
GLYCOPEPTIDES;
HUMANS;
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;
MIDDLE AGED;
SOFT TISSUE INFECTIONS;
STAPHYLOCOCCAL SKIN INFECTIONS;
STAPHYLOCOCCUS AUREUS;
TEICOPLANIN;
VANCOMYCIN;
|
EID: 82955227441
PISSN: 09248579
EISSN: 18727913
Source Type: Journal
DOI: 10.1016/j.ijantimicag.2011.08.007 Document Type: Letter |
Times cited : (28)
|
References (5)
|